{"podcast":{"title":"Hims House","slug":"hims-house-7026583","podcast_index_feed_id":7026583,"rss_url":"https://anchor.fm/s/10e9c0874/podcast/rss","website_url":"https://himshouse.substack.com/podcast","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/45300741/1466fea8bed61dc7.jpg","author":"Jonathan Stern","episode_count":78,"summary":"Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com","last_synced_at":"2026-09-03T00:18:07.225175+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583"},"episode":{"title":"Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro","slug":"bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro","published_at":"2026-08-26T13:00:16+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583/bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro","show_page_url":"https://stenobird.com/podcast/hims-house-7026583","url":"https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Bijan-Salehizadeh---Eli-Lillys-War-on-Compounded-GLP-1s--Peptides--Retatrutide--and-Hims-vs-Ro-e3ntrv4","audio_url":"https://anchor.fm/s/10e9c0874/podcast/play/124759460/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-7-26%2F430576030-44100-2-86a0a6f9ed778.mp3","summary":"In episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pharma prefers interim commissioner Kyle Diamantis. They then move to Eli Lilly's multi-front war on compounded GLP-1s, the ReviveRx suit, the effort to pull semaglutide and tirzepatide off the 503B bulks list, and Bijan's theory of a "grand bargain" trading compounding restrictions for Medicare pricing cooperation. He walks through the retatrutide biologic fight ahead of the September 24th appellate argument in Chicago, and why Hims' 76% gross margins are gone for good as branded dispensing grows. They close on peptides: Bijan has heard Category 1 rulemaking *could* come as soon as November, and he thinks the market could be 10x bigger than current estimates. 00:00 - Sponsor: Superpower 01:16 - No one knows anything about Heidi Overton (FDA nominee) 06:29 - Eli Lilly's war on 503A pharmacies 08:47 - The Lilly "grand bargain" 13:49 - When compounding becomes a "new drug" 17:34 - Branded drugs crush margins 21:51 - Hims management scorecard 26:29 - Retatrutide reclassification fight 35:10 - Suing the reta gray market vendors 37:06 - Why the Wegovy pill is beating Foundayo 40:56 - Europe is a second-tier market 42:15 - Can LillyDirect beat telehealth? 46:14 - Peptides Wild West 50:51 - Category 1 by November? 52:40 - Peptides market 10x bigger than estimates 55:56 - Will Ro go public? 58:34 - Bullish $HIMS long term Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discuss…","meta_description":"In episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, foun…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3629,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hims-house-7026583/bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}